![]() Infusion: Administer via calibrated electronic controlled-infusion device Storage Injection: Administer slowly over 10 minutes may use undiluted for initial direct IV injection Infusion: Dilute in NS, 1/2NS, or D5W to 200 mcg/mL use undiluted if giving 20 mg/100 mL in D5W IV Administration Injection: Dilute in NS, 1/2NS, or D5W to 10-20 mL Y-site (partial list): Acyclovir, amiodarone, calcium chloride, calcium gluconate, ciprofloxacin, digoxin, diltiazem, dobutamine, dopamine, epinephrine, fentanyl, heparin, lorazepam, magnersium sulfate, metronidazole, midazolam, morphine sulfate, nitroglycerin, norepinephrine, potassium chloride, propofol, propranolol, quinidine, sodium nitroprusside, vancomycin IV Preparation Syringe: Atropine, calcium chloride, digoxin, epinephrine, lidocaine, morphine sulfate, propranolol, sodium bicarbonate, verapamil Y-site: Furosemide, procainamide IV Compatibilities Serious - Use Alternative (1)ponesimod, milrinone. Monitor for hypertension with concomitant use. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Serious - Use Alternative (1)ozanimod increases toxicity of milrinone by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)milrinone, inamrinone. ![]() Monitor Closely (1)dichlorphenamide and milrinone both decrease serum potassium. Monitor Closely (1)milrinone, cilostazol. Monitor Closely (1)anagrelide, milrinone. Riociguat is contraindicated with specific PDE-5 inhibitors (eg sildenafil, tadalafil, vardenafil) and nonspecific PDE-5 inhibitors (eg theophylline, dipyridamole) due to risk of hypotension data are limited with other PDE inhibitors. ![]() Use Caution/Monitor.Įither increases effects of the other by additive vasodilation. Use Caution/Monitor.ĭichlorphenamide and milrinone both decrease serum potassium. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients.Įither increases effects of the other by pharmacodynamic synergism. Consult cardiologist if considering treatment. Monitor for hypertension with concomitant use.Įither increases effects of the other by pharmacodynamic synergism. Ozanimod increases toxicity of milrinone by sympathetic (adrenergic) effects, including increased blood pressure and heart rate.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |